Corbus Pharmaceuticals Holding Stock Performance
| CRBP Stock | USD 7.63 0.21 2.83% |
The firm shows a Beta (market volatility) of 0.86, which signifies possible diversification benefits within a given portfolio. Corbus Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Corbus Pharmaceuticals is expected to follow. At this point, Corbus Pharmaceuticals has a negative expected return of -0.64%. Please make sure to confirm Corbus Pharmaceuticals' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Corbus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Corbus Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in March 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 2.83 | Five Day Return 2.97 | Year To Date Return (3.05) | Ten Year Return (80.44) | All Time Return (91.52) |
Last Split Factor 1:30 | Last Split Date 2023-02-14 |
1 | Acquisition by Cormorant Asset Management, Lp of 25769 shares of Corbus Pharmaceuticals at 22.228 subject to Rule 16b-3 | 12/05/2025 |
2 | Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Prof... | 12/11/2025 |
3 | Corbus Pharmaceuticals Holdings Inc. Stock Slides 8.6, Underperforms Peers - | 12/17/2025 |
4 | Downgrade Watch Will Corbus Pharmaceuticals Holdings Inc 3371 stock top growth indexes - Market Growth Summary Daily Volume Surge Trade Alerts - moha.gov.vn | 12/23/2025 |
5 | Corbus Pharmaceuticals Holdings, Inc. Receives Consensus Rating of Moderate Buy from Brokerages - MarketBeat | 12/29/2025 |
6 | The 3 Best Cannabis Stocks to Buy for 2026 | 01/09/2026 |
7 | Acquisition by Ian Hodgson of 28365 shares of Corbus Pharmaceuticals subject to Rule 16b-3 | 01/14/2026 |
8 | While institutions invested in Corbus Pharmaceuticals Holdings, Inc. benefited from last weeks 12 percent gain, individual investors stood to gain the most | 01/27/2026 |
9 | Disposition of 2415 shares by Ian Hodgson of Corbus Pharmaceuticals at 8.0899 subject to Rule 16b-3 | 02/03/2026 |
10 | Corbus Pharmaceuticals COO Ian Hodgson Sells 2,415 Shares | 02/05/2026 |
11 | Disposition of 13871 shares by Yuval Cohen of Corbus Pharmaceuticals at 7.7826 subject to Rule 16b-3 | 02/13/2026 |
| Begin Period Cash Flow | 14.4 M | |
| Total Cashflows From Investing Activities | -121.3 M |
Corbus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,154 in Corbus Pharmaceuticals Holding on November 27, 2025 and sell it today you would lose (391.00) from holding Corbus Pharmaceuticals Holding or give up 33.88% of portfolio value over 90 days. Corbus Pharmaceuticals Holding is currently does not generate positive expected returns and assumes 3.4036% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Corbus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corbus Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Corbus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 7.63 | 90 days | 7.63 | about 82.86 |
Based on a normal probability distribution, the odds of Corbus Pharmaceuticals to move above the current price in 90 days from now is about 82.86 (This Corbus Pharmaceuticals Holding probability density function shows the probability of Corbus Stock to fall within a particular range of prices over 90 days) .
Corbus Pharmaceuticals Price Density |
| Price |
Predictive Modules for Corbus Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Corbus Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Corbus Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Corbus Pharmaceuticals is not an exception. The market had few large corrections towards the Corbus Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Corbus Pharmaceuticals Holding, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Corbus Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.72 | |
β | Beta against Dow Jones | 0.86 | |
σ | Overall volatility | 1.36 | |
Ir | Information ratio | -0.22 |
Corbus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Corbus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Corbus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Corbus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corbus Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (40.21 M) with loss before overhead, payroll, taxes, and interest of (32.96 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (41.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Corbus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Brigitte Lindsay of 200000 shares of Cardiff Oncology at 1.6 subject to Rule 16b-3 |
Corbus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Corbus Stock often depends not only on the future outlook of the current and potential Corbus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Corbus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.9 M | |
| Cash And Short Term Investments | 149.1 M |
Corbus Pharmaceuticals Fundamentals Growth
Corbus Stock prices reflect investors' perceptions of the future prospects and financial health of Corbus Pharmaceuticals, and Corbus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corbus Stock performance.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 45.3 M | ||||
| Shares Outstanding | 17.55 M | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1.44 X | ||||
| Price To Sales | 163.32 X | ||||
| Gross Profit | (32.96 M) | ||||
| EBITDA | (37.74 M) | ||||
| Net Income | (40.21 M) | ||||
| Cash And Equivalents | 66.23 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 3.24 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | 7.35 X | ||||
| Cash Flow From Operations | (41.79 M) | ||||
| Earnings Per Share | (5.49) X | ||||
| Market Capitalization | 130.24 M | ||||
| Total Asset | 155.88 M | ||||
| Retained Earnings | (476.89 M) | ||||
| Working Capital | 141.16 M | ||||
| Current Asset | 12.71 M | ||||
| Current Liabilities | 3.63 M | ||||
About Corbus Pharmaceuticals Performance
Assessing Corbus Pharmaceuticals' fundamental ratios provides investors with valuable insights into Corbus Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Corbus Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (12.56) | (11.93) | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.32) | (0.34) |
Things to note about Corbus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Corbus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corbus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corbus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Corbus Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (40.21 M) with loss before overhead, payroll, taxes, and interest of (32.96 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (41.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Corbus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Brigitte Lindsay of 200000 shares of Cardiff Oncology at 1.6 subject to Rule 16b-3 |
- Analyzing Corbus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corbus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Corbus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corbus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corbus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corbus Pharmaceuticals' stock. These opinions can provide insight into Corbus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.